title: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
authors.forename: E
authors.initials: E
authors.lastname: Lopez-Crapez
authors.forename: L
authors.initials: L
authors.lastname: Mineur
authors.forename: H
authors.initials: H
authors.lastname: Emptas
authors.forename: P-J
authors.initials: PJ
authors.lastname: Lamy
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000276:immunology*; D011905:Genes, ras; D006801:Humans; D008297:Male; D018447:Medical Futility; D009154:Mutation / Q000502:physiology; D009362:Neoplasm Metastasis
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C512478:EGFR protein, human; D066246:ErbB Receptors